Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

French Trial Tragedy May Spark Change In EU Phase I Risk Assessments 

This article was originally published in SRA

Executive Summary

Drug regulators in the EU are looking closely at the way that Phase I studies are planned and designed amid calls for better protection for volunteers in the wake of the French BIA 10-2474 trial tragedy. Among topics likely to be under consideration are a more consistent approach to determining the potential risk of novel compounds, and greater use of sequential dosing in first-in-human clinical trials.

Advertisement
Advertisement
UsernamePublicRestriction

Register